Vildagliptin-Induced Thrombocytopenia: A Case Report with Pharmacovigilance Perspective
Vildagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor widely used in type 2 diabetes mellitus, is generally considered well-tolerated. We report a case of a 62-year-old woman who developed progressive, isolated thrombocytopenia approximately ten months after initiating vildagliptin 50 mg…...
10.5281/zenodo.21852173